628-12-6

应用筛选条件

关键词:'628-12-6'

显示 1-4 共 4 条结果关于 "628-12-6" 范围论文

Four weeks of normobaric "live high-train low" do not alter muscular or systemic capacity for maintaining pH and K⁺ homeostasis during intense exercise.

N B Nordsborg et al.

Journal of applied physiology (Bethesda, Md. : 1985), 112(12), 2027-2036 (2012-03-31)

It was investigated if athletes subjected to 4 wk of living in normobaric hypoxia (3,000 m; 16 h/day) while training at 800-1,300 m ["live high-train low" (LHTL)] increase muscular and systemic capacity for maintaining pH and K(+) homeostasis as well

Exploring Chronic Drug Effects on Microengineered Human Liver Cultures Using Global Gene Expression Profiling.

Brenton R Ware et al.

Toxicological sciences : an official journal of the Society of Toxicology, 157(2), 387-398 (2017-04-04)

Global gene expression profiling is useful for elucidating a drug's mechanism of action on the liver; however, such profiling in rats is not very sensitive for predicting human drug-induced liver injury, while dedifferentiated monolayers of primary human hepatocytes (PHHs) do

[The correlation between dendritic cell-specific ICAM-3 grabbing nonintegrin expression and Mycobacterium tuberculosis in humans].

Jie Zhang et al.

Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases, 32(8), 572-575 (2009-12-05)

To investigate the correlation between dendritic cell-specific ICAM-3 grabbing nonintegrin (DC-SIGN) expression and Mycobacterium tuberculosis in humans. The peripheral blood mononuclear cells were obtained respectively from 25 patients with tuberculosis, 25 patients with pneumonia and 25 healthy individuals, and were

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial.

Edward B Garon et al.

Lancet (London, England), 384(9944), 665-673 (2014-06-17)

Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC)

1/1